▲ S&P 500 +---%|▲ Stock Advisor +---%Join The Motley Fool

AccessibilityHelp

Leo Sun

TMFSunLion

Leo Sun is a contributing Motley Fool stock market analyst who has worked with the company since 2013, covering technology, consumer goods, industrial, and financial sectors. He became a self-made millionaire by age 40 through long-term investing, crediting lessons from Warren Buffett and Peter Lynch. Leo is a regular guest on CNBC Asia providing stock analysis on Chinese technology companies, including Tencent, Baidu, and Alibaba. He previously wrote for InvestorGuide and holds a bachelor’s degree in English from the University of Texas at Austin.

Articles by Leo Sun — Page 471

Will Johnson & Johnson's New Alzheimer's Partnership Unlock New Potential Treatments?

Nov 18, 2013 by Leo Sun

Will Johnson & Johnson's New Alzheimer's Partnership Unlock New Potential Treatments?

Johnson & Johnson recently signed a deal with Evotec to go back to the drawing board and develop new treatments for Alzheimer’s disease. What does this deal mean for Pfizer, Eli Lilly, Merck, and AstraZeneca, which have also been pursuing the same goal?

Sony’s PS4 'Blue Light of Death' Hardware Failures Could Be Foxconn’s Fault

Nov 18, 2013 by Leo Sun

Sony’s PS4 'Blue Light of Death' Hardware Failures Could Be Foxconn’s Fault

Sony’s PS4 got off to a strong start last weekend, selling more than 1 million units in North America within the first 24 hours. But reports of hardware failures overshadowed those figures. Is Foxconn, the controversial manufacturer most often associated with Apple, to blame for this debacle?

Why You Should Watch Sanofi, Salix, Akorn, and Isis Today

Nov 18, 2013 by Leo Sun

Why You Should Watch Sanofi, Salix, Akorn, and Isis Today

Sanofi, Salix, Akorn, and Isis are four stocks you should be watching today. Here’s why.

800px-Nike_FuelBand

Nov 17, 2013 by Leo Sun

3 Ways Wearable Technology Could Revolutionize Human Health Over the Next 10 Years

Wearable tech is the tech industry's favorite buzzword these days. However, the adoption of new wearable tech will also impact the health care industry over the next decade. Let's take a look at how new products from Nike, Medtronic, and Google are changing how we view personal fitness and health care.

What Does a Mixed FDA Verdict Mean for Sanofi's MS Drug?

Nov 16, 2013 by Leo Sun

What Does a Mixed FDA Verdict Mean for Sanofi's MS Drug?

An FDA panel recently recommended the approval of Sanofi's MS drug, Lemtrada, but the verdict on its efficacy and safety was mixed. How will the drug fare in the crowded market of MS treatments currently dominated by Novartis, Biogen Idec, and Teva?

Why Aren't Investors More Excited About Pharmacyclics' FDA Approval?

Nov 14, 2013 by Leo Sun

Why Aren't Investors More Excited About Pharmacyclics' FDA Approval?

Pharmacyclics and Johnson & Johnson recently received Food and Drug Administration approval for their eagerly anticipated blood disorder treatment, Imbruvica. What does this mean for industry peers Celgene and Gilead Sciences, which are also developing treatments for similar indications?

Novartis Reports Positive Results for Avian Flu Vaccine

Nov 14, 2013 by Leo Sun

Novartis Reports Positive Results for Avian Flu Vaccine

Novartis just announced positive interim trial results for its H7N9 vaccine. Will this development affect other companies in the flu vaccine and treatment industry, such as Roche, Gilead, GlaxoSmithKline, and Biota Pharmaceuticals?

How Did This Company Lose Over $6 Billion in 2 Weeks?

Nov 13, 2013 by Leo Sun

How Did This Company Lose Over $6 Billion in 2 Weeks?

In two weeks, Johnson & Johnson has reached two tentative settlements that could cost the company more than $6 billion. How will these two events affect the big pharma's future?

Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today

Nov 13, 2013 by Leo Sun

Why Sinovac, Pluristem, and Synta Could Be Worth Watching Today

Sinovac, Pluristem, and Synta Pharmaceuticals might all be worth a look today. Let's take a look at the headlines that could move these three stocks.

Why Google Drive Has Become Microsoft’s Worst Nightmare

Nov 12, 2013 by Leo Sun

Why Google Drive Has Become Microsoft’s Worst Nightmare

Google’s family of cloud-based apps have become essential tools for everyday productivity for many people. How was Google able to so quickly turn the tables on Microsoft, which had been the dominant force in both operating systems and productivity software?

Who Will Buy This Medical Giant's Diagnostics Business?

Nov 12, 2013 by Leo Sun

Who Will Buy This Medical Giant's Diagnostics Business?

Several major companies are now interested in acquiring J&J’s fading Ortho Clinical Diagnostics business, but which one will place the top bid?

Why You Should Be Watching Sarepta, Hologic, and Achillion Today

Nov 12, 2013 by Leo Sun

Why You Should Be Watching Sarepta, Hologic, and Achillion Today

Sarepta Therapeutics, Hologic, and Achillion Pharmaceuticals are three stocks worth watching today. Let’s check in on the headlines behind these price movements.

Is This Orphan Drugmaker in Trouble?

Nov 11, 2013 by Leo Sun

Is This Orphan Drugmaker in Trouble?

Protalix’s joint venture with Pfizer to bring a new Gaucher disease treatment to the market has had a rough start. Is the company doomed to be buried by its entrenched rivals, Sanofi and Shire?

Blizzard Reveals World of Warcraft Expansion Warlords of Draenor and More at BlizzCon 2013

Nov 11, 2013 by Leo Sun

Blizzard Reveals World of Warcraft Expansion Warlords of Draenor and More at BlizzCon 2013

Blizzard revealed some key details regarding its core franchises at BlizzCon last weekend, including Warlords of Draenor, the latest expansion to World of Warcraft. Here are all the top stories that you should be paying attention to.

Why You Should Keep an Eye on Shire, ViroPharma, and Novartis Today

Nov 11, 2013 by Leo Sun

Why You Should Keep an Eye on Shire, ViroPharma, and Novartis Today

Shire, ViroPharma and Novartis could make interesting moves today. Let's check in on the headlines moving these stocks.

Will Biosimilars Unlock This Company's Long-Term Potential?

Nov 9, 2013 by Leo Sun

Will Biosimilars Unlock This Company's Long-Term Potential?

Hospira has faced some major problems in its medical devices business after a damaging FDA ban. However, many investors are overlooking the company’s long-term growth potential in biosimilars.

Will This Medical Device Maker Keep Sliding?

Nov 8, 2013 by Leo Sun

Will This Medical Device Maker Keep Sliding?

Medical device maker Volcano has had a tough month after reporting dismal earnings and a bleak sales forecast. Will shares continue to fall, or is the sell-off almost over?

Call of Duty: Ghosts Sales Hit $1 Billion in a Day, Keeps Activision’s Self-Sustaining Cash Cow Alive

Nov 8, 2013 by Leo Sun

Call of Duty: Ghosts Sales Hit $1 Billion in a Day, Keeps Activision’s Self-Sustaining Cash Cow Alive

Sales of the latest installment of the Call of Duty franchise have hit $1 billion in sales in a single day. Let’s take a look at the magic formula that keeps Activision Blizzard’s top franchise profitable after a decade of releases.

New Humble Bundle Features WB Games, Great Charitable Bargains for Gamers

Nov 7, 2013 by Leo Sun

New Humble Bundle Features WB Games, Great Charitable Bargains for Gamers

Now that EA and WB Games have offered their own Humble Bundles, will other major publishers follow in their footsteps?

Will Assassin's Creed 4 Be the Last Yearly Update to the Franchise?

Nov 6, 2013 by Leo Sun

Will Assassin's Creed 4 Be the Last Yearly Update to the Franchise?

Ubisoft has impressively delivered six Assassin's Creed titles within six years -- but is its business model sustainable?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services